Cost savings calculator

Where we can, we will always try to provide our medicines to the NHS at responsible and appropriate prices. We believe a simple, transparent List Price is the best way of doing this. We know that NHS resources are precious, and we try to ensure that our products help to reduce prescribing costs.

CEYESTO® 1mg/ml Oral Solution is indicated for Delayed Sleep Wake Phase Disorder (DSWPD) in children and adolescents aged 6-17 years and adults up to 25 years of age, where sleep hygiene measures have been insufficient, Insomnia in children and adolescents aged 6-17 years with Attention Deficit Hyperactivity Disorder (ADHD), where sleep hygiene measures have been insufficient, single use for short-term sedation under medical supervision to facilitate electroencephalograms (EEGs) in children and adolescents from 1 to 18 years, and the short term treatment of jet lag in adults.

Proportion of patients prescribed melatonin for DSWPD, insomnia with ADHD, sedation pre-EEG, or jet lag in your area

CEYESTO® 1mg/ml Oral Solution is indicated for Delayed Sleep Wake Phase Disorder (DSWPD) in children and adolescents aged 6-17 years and adults up to 25 years of age, where sleep hygiene measures have been insufficient, Insomnia in children and adolescents aged 6-17 years with Attention Deficit Hyperactivity Disorder (ADHD), where sleep hygiene measures have been insufficient, single use for short-term sedation under medical supervision to facilitate electroencephalograms (EEGs) in children and adolescents from 1 to 18 years, and the short term treatment of jet lag in adults.

The recommended dose ranges, and the timing of dosing, for these four separate indications can be found here Ceyesto® 1mg/ml Oral Solution – Indications and Dosing .

This interactive slider is intended to be used to generate illustrative scenarios only. Please contact us for alternative scenarios tailored to your locality.

Percentage conversions

The user can select one of four conversion scenarios. These are intended for illustrative scenarios only. Please contact us for alternative scenarios tailored to your locality.
Melatonin 3mg tablets indicated for the short-term treatment of jet lag in adults, and for insomnia in children and adolescents aged 6-17 years with ADHD, where sleep hygiene measures have been insufficient.

Proportion of paediatric and adolescent patients with ADHD prescribed melatonin for insomnia

CEYESTO® 3mg tablets are indicated for the short-term treatment of jet lag in adults, and for insomnia in children and adolescents aged 6-17 years with ADHD, where sleep hygiene measures have been insufficient. The standard dose in adult jet lag is one 3mg tablet daily, taken at the local bedtime on arrival at the travel destination for a maximum of four days. The dose for insomnia in children and adolescents aged 6-17 years with ADHD is one 3 mg tablet which should be taken 30-60 minutes before bedtime.

This interactive slider is intended to be used to generate illustrative scenarios only. Please contact us for alternative scenarios tailored to your locality.

Percentage conversions

The user can select one of four conversion scenarios. These are intended for illustrative scenarios only. Please contact us for alternative scenarios tailored to your locality.
Concentrated desmopressin oral solution containing 360 micrograms of anhydrous desmopressin indicated for the treatment of central diabetes insipidus, and the treatment of primary nocturnal enuresis in patients (over 5 years) with normal capacity to concentrate urine.

Percentage conversions

The user can select one of four conversion scenarios. These are intended for illustrative scenarios only. Please contact us for alternative scenarios tailored to your locality.
Effervescent N-Acetylcysteine 600mg. Indicated for the treatment of respiratory disorders in adults

4 or 52 weeks?

This model compares NACSYS with carbocisteine, in terms of cost. The recommended licensed initial dose of carbocisteine is 2,250mg daily, reducing to 1,500mg daily when a satisfactory response is obtained. The user can select a short initiation dose period (of 4 weeks) or continuation of this higher dose for a full 52 weeks. These are intended for illustrative scenarios only. Please contact us for alternative scenarios tailored to your locality.

Percentage conversions

The user can select one of four conversion scenarios. These are intended for illustrative scenarios only. Please contact us for alternative scenarios tailored to your locality.
Modified Release Sodium Chloride 600mg tablets indicated for the treatment and prevention of sodium chloride deficiency.

Percentage conversions

The user can select one of four conversion scenarios. These are intended for illustrative scenarios only. Please contact us for alternative scenarios tailored to your locality.
Effervescent Potassium Chloride 600mg Potassium Bicarbonate 400mg tablets indicated for prevention and treatment of low potassium levels caused by a range of underlying conditions.

Percentage conversions

The user can select one of four conversion scenarios. These are intended for illustrative scenarios only. Please contact us for alternative scenarios tailored to your locality.
Calculate Savings
{!calculation.total.formatted.diff!}
  • {!calculation.total.formatted.before!}
  • {!calculation.total.formatted.after!}
  • {!calculation.total.formatted.diff!}
  • {!calculation.nacsys.result.formatted.diff!}
  • {!calculation.ceyesto.result.formatted.diff!}
  • {!calculation.slow_sodium.result.formatted.diff!}
  • {!calculation.sando_k.result.formatted.diff!}
  • {!calculation.demovo.result.formatted.diff!}
  • {!calculation.ceyesto_os.result.formatted.diff!}
Change Settings
{!calculation.total.formatted.before!}
{!calculation.total.formatted.after!}
NACSYS - Potential savings are calculated for {!calculation.nacsys.data.pco!} and are based on all carbocisteine patients being on the high dose for {!calculation.nacsys.result.weeks!} weeks, and conversion of {!calculation.nacsys.result.percent!}% of all patients to NACSYS. Please change these settings for alternative scenarios.
CEYESTO Tablets - Potential savings are calculated for {!calculation.ceyesto.data.pco!} and are based on the conversion of {!calculation.ceyesto.result.percent!}% of patients to CEYESTO Tablets.
SLOW SODIUM - Potential savings are calculated for {!calculation.slow_sodium.data.pco!} and are based on the conversion of {!calculation.slow_sodium.result.percent!}% of patients to SLOW SODIUM.
SANDO-K - Potential savings are calculated for {!calculation.sando_k.data.pco!} and are based on the conversion of {!calculation.sando_k.result.percent!}% of patients to SANDO-K.
DEMOVO - Potential savings are calculated for {!calculation.demovo.data.pco!} and are based on the conversion of {!calculation.demovo.result.percent!}% of patients to DEMOVO.
CEYESTO Oral Solution - Potential savings are calculated for {!calculation.ceyesto_os.data.pco!} and are based on the conversion of {!calculation.ceyesto_os.result.percent!}% of patients to CEYESTO Oral Solution.

Need more information?

Contact us now for a more in depth review of your potential savings

HOW WE CALCULATE YOUR POTENTIAL SAVINGS

The purpose of this direct cost comparison model is to show the differences in drug acquisition costs of our products and their competitors.

This model makes no attempt to show the cost of outcomes on a particular treatment or the impact on outcomes of changing from one product to another, it is solely to be used to articulate differences in acquisition costs.

The model calculates the price difference between acquisition costs of our products and their competitors, based on the volume of prescribing and the comparators' price.

For Slow Sodium, and Sando-K, the mg content of sodium and potassium in competitor products was used to calculate the equivalent number of Slow Sodium or Sando-K tablets from the reported quantity in the prescribing data.

For Demovo, the equivalent mL calculation was based on: 180 mcg Demovo = 200 mcg desmopressin tablets = 120 mcg desmopressin lyophilisates = 180 mcg desmopressin oral liquids.

Where available, the Drug Tariff price was used to source prices of comparators, followed by the DM+D price. Where a price was not listed , the cost of prescribing reported in the prescribing data was used. Please note that in this instance, the cost of prescribing is retrospective and may not reflect the current cost of these products.

The price of 30 x NACSYS 600mg effervescent tablets is £5.50.
The price of 30 x CEYESTO 3mg tablets is £10.99.
The price of 100 x Slow Sodium tablets is £9.20.
The price of 100 x Sando-K tablets is £9.95.
The price of 15 ml x Demovo 360 mcg/ml oral solution is £19.95.
The price for CEYESTO® Oral Solution 1mg/ml is £25.65 for a 150ml bottle, and £17.10 for a 100ml bottle.

The BNF code was used for all products at the AMPP level.

PRESCRIBING DATA SOURCES

Open Prescribing.

Explore England's prescribing data. Available at https://openprescribing.net/. Extract date: {!extract_date!}

Health and Social Care Business Services Organisation.

Prescribing by GP Practice Datasets. Available at http://gpdatasets.hscni.net/. Extract date: {!extract_date!}

NHS BSA.

English Prescribing Dataset (EPD). Available at https://opendata.nhsbsa.net/dataset/english-prescribing-data-epd.

NHS National Services Scotland.

Themes / Health and care / Prescriptions in the Community. Available at https://www.opendata.nhs.scot/dataset/prescriptions-in-the-community . Extract date: {!extract_date!}

NHS Wales Shared Services Partnership.

General Practice Prescribing Data Extract. Available at http://www.primarycareservices.wales.nhs.uk/general-practice-prescribing-data-extract . Extract date: {!extract_date!}

OpenData NI.

GP Prescribing Data. Available at https://www.opendatani.gov.uk/dataset/gp-prescribing-data .

Success stories

I have worked with the team at ALTURiX for over twenty years now. They understand the challenges I face, and have always been constructive in our interactions, adding value wherever they can.